Serum calcium, phosphorus and cardiovascular events in post-menopausal women

International Journal of Cardiology

Volumn 149, Issue 3, 2011, Pages 335-340

  Slinin, Yelena ^a,b   Blackwell, Terri ^c   Ishani, Areef ^a,b   Cummings, Steven R ^c   Ensrud, Kristine E ^a,b,d  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Calcium; Cardiovascular disease; Phosphorus

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; COLECALCIFEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; RALOXIFENE; VITAMIN D;

AGED; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OSTEOPOROSIS; PHOSPHORUS; POSTMENOPAUSE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79958180014     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.02.013     Document Type: Article

References (28)

1. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet 1998;352:391-6. (Pubitemid 28352214)
2. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-7.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
5. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-9. (Pubitemid 38294808)
6. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93. (Pubitemid 41716485)
7. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8. (Pubitemid 41725150)
8. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008;199:424-31.
9. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33. (Pubitemid 41532599)
10. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85. (Pubitemid 46762749)
11. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008;156:556-63.
12. Onufrak SJ, Bellasi A, Cardarelli F, et al. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and allcause mortality. Am J Epidemiol 2009;169:67-77.
13. Neves KR, Graciolli FG, dos Reis LM, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007;71:1262-70.
14. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-20. (Pubitemid 46193327)
15. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. (Pubitemid 29384151)
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
17. Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006;97:520-7. (Pubitemid 43190043)
18. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83. (Pubitemid 30318271)
19. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24. (Pubitemid 43169927)
20. Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch Intern Med 2007;167:2437-42.
21. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004;164:1285-92. (Pubitemid 38828878)
22. Narang R, Ridout D, Nonis C, Kooner JS. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 1997;60:73-9. (Pubitemid 27288259)
23. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262-6. (Pubitemid 351251627)
24. Reid IR, Ames R, Mason B, et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008;168:2276-82.
25. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-54. (Pubitemid 46294725)
26. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57. (Pubitemid 34252031)
27. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37. (Pubitemid 44050394)
28. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.